Matthew Anstey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Matthew Anstey has a total of 343 co-authors. Here are the top co-authors by number of shared publications:
- Bradley Wibrow
Sir Charles Gairdner Hospital
14 shared publications Bradley Wibrow
Affiliations Intensive Care Department, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia, School of Medicine, University of Western Australia, Perth, Western Australia, Australia
12 shared publications- Kwok Ming Ho
The Chinese University of Hong Kong
9 shared publications - Edward Litton
Fiona Stanley Hospital
7 shared publications Angela Jacques
Affiliation Institute for Health Research, University of Notre Dame, Fremantle, Western Australia, Australia
6 shared publications- Angela Jacques
Research Department, Perth Children’s Hospital, Child and Adolescent Health Service, Perth, WA 6009, Australia
5 shared publications
Latest Publications
- Open Access
- 6 July 2026
- Published by Springer Nature in Research Square
Perioperative Considerations and Outcomes of the Hybrid Convergent Procedure for Atrial Fibrillation: A Prospective Observational Study
Objective To characterize the perioperative course, early complications, and rhythm outcomes of patients undergoing the hybrid convergent procedure for atrial fibrillation, with emphasis on implications for anesthetic and critical care management. Design and Setting Prospective observational cohort study based at a single-center private hospital. Participants Sixty-two patients with symptomatic paroxysmal or persistent atrial fibrillation refractory to class I/III anti-arrhythmic therapy undergoing the surgical stage of the hybrid convergent procedure; perioperative data were available for 55 patients. Interventions Thoracoscopic subxiphoid epicardial ablation of the posterior left atrial wall with concomitant left atrial appendage occlusion, followed by staged endocardial catheter ablation. All patients were admitted postoperatively to the intensive care unit. Measurements & Main Results Mean ICU length of stay was 25.2 ± 13.3 hours. Inotropic support was required in 7.3% of patients, and no patients required postoperative mechanical ventilation. Major complications were uncommon, with no mortality, stroke, or cardiac tamponade. Pericarditis was common and occurred in 25.5% of patients. Troponin and BNP levels rose postoperatively, peaking on day 3. Postoperative atrial fibrillation occurred in 23.7% of patients by day 3. At 12 months, 62.9% of patients were free from atrial arrhythmia, 58.1% were off anti-arrhythmic therapy, and 75.8% had < 5% atrial fibrillation burden. Conclusions The hybrid convergent procedure demonstrates a favorable perioperative profile, characterized by short ICU stay, low rates of major complications, and limited need for advanced critical care support. Although early postoperative arrhythmias and pericarditis are common, longer-term outcomes show meaningful reductions in atrial fibrillation burden. These findings have important implications for perioperative and critical care management of this evolving patient population.
- 6 July 2026
- Published by Springer Nature in Research Square
Open AccessPerioperative Considerations and Outcomes of the Hybrid Convergent Procedure for Atrial Fibrillation: A Prospective Observational Study
Objective To characterize the perioperative course, early complications, and rhythm outcomes of patients undergoing the hybrid convergent procedure for atrial fibrillation, with emphasis on implications for anesthetic and critical care management. Design and Setting Prospective observational cohort study based at a single-center private hospital. Participants Sixty-two patients with symptomatic paroxysmal or persistent atrial fibrillation refractory to class I/III anti-arrhythmic therapy undergoing the surgical stage of the hybrid convergent procedure; perioperative data were available for 55 patients. Interventions Thoracoscopic subxiphoid epicardial ablation of the posterior left atrial wall with concomitant left atrial appendage occlusion, followed by staged endocardial catheter ablation. All patients were admitted postoperatively to the intensive care unit. Measurements & Main Results Mean ICU length of stay was 25.2 ± 13.3 hours. Inotropic support was required in 7.3% of patients, and no patients required postoperative mechanical ventilation. Major complications were uncommon, with no mortality, stroke, or cardiac tamponade. Pericarditis was common and occurred in 25.5% of patients. Troponin and BNP levels rose postoperatively, peaking on day 3. Postoperative atrial fibrillation occurred in 23.7% of patients by day 3. At 12 months, 62.9% of patients were free from atrial arrhythmia, 58.1% were off anti-arrhythmic therapy, and 75.8% had < 5% atrial fibrillation burden. Conclusions The hybrid convergent procedure demonstrates a favorable perioperative profile, characterized by short ICU stay, low rates of major complications, and limited need for advanced critical care support. Although early postoperative arrhythmias and pericarditis are common, longer-term outcomes show meaningful reductions in atrial fibrillation burden. These findings have important implications for perioperative and critical care management of this evolving patient population.
- Open Access
- 17 June 2026
- Published by Springer Nature in Intensive Care Medicine
- Vol. 52 (8) , 1-3
How important is the ABCDE bundle to patient functioning after ICU?
- 17 June 2026
- Published by Springer Nature in Intensive Care Medicine
- Vol. 52 (8) , 1-3
Open AccessHow important is the ABCDE bundle to patient functioning after ICU?
- 15 June 2026
- Published by Springer Nature in Intensive Care Medicine
- Vol. 52 (8) , 1759-1761
Making the environmental case for digital education in intensive care
- 15 June 2026
- Published by Springer Nature in Intensive Care Medicine
- Vol. 52 (8) , 1759-1761
Making the environmental case for digital education in intensive care
- Open Access
- 16 March 2026
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 54 (4) , 701-714
Influence of Age in End-of-Life Practices in Worldwide ICUs (ETHICUS-2): A Prospective Observational Study
OBJECTIVES: The practice of limiting life-sustaining therapy (LST) at end-of-life is widespread globally. The goal of this study was to evaluate whether patient’s age influences end-of-life limitations overall and of various LST in ICUs worldwide. DESIGN: Multinational, multicenter, prospective observational study. SETTING: One hundred ninety-nine ICUs in 36 countries worldwide. PATIENTS: Consecutive adult patients admitted to ICUs who died and/or had LST limitations (withholding, withdrawing, or active shortening of the dying process) were included during a 6-month period between September 2015 and September 2016. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Patients were grouped: younger than 65 years, 65–79 years old, and 80 years old or older. A total of 12,200 patients were included. In multivariate logistic regression analysis, odds ratio (OR) for any LST limitation in the 80 years old or older group was higher than in younger than the 65 years old group (OR 1.47 [95% CI, 1.22–1.76], p < 0.001). When stratified by region, this association was significant in Central and Southern Europe (OR 1.56 [95% CI, 1.11–2.20], p = 0.037 and OR 2.23 [95% CI, 1.58–3.17], p < 0.001, respectively), but not in the other regions. The proportion of withholding therapy of each LST was highest in the group of individuals 80 years or older, whereas the proportion of withdrawing therapy was highest in the group younger than 65 years. The 80-year-old or older group also had a shorter time from ICU admission to first limitation. The predominant reason for any LST limitation in all age groups was unresponsiveness to maximal therapy, followed by neurologic and chronic diseases. Patient age was rarely the primary reason for limitations for all groups. CONCLUSIONS: End-of-life limitations were higher in patients 80 years or older compared to those 65 years old or younger, with regional variations. The main reasons for limitations were comparable across age groups, with age not being the primary reason.
- 16 March 2026
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 54 (4) , 701-714
Open AccessInfluence of Age in End-of-Life Practices in Worldwide ICUs (ETHICUS-2): A Prospective Observational Study
OBJECTIVES: The practice of limiting life-sustaining therapy (LST) at end-of-life is widespread globally. The goal of this study was to evaluate whether patient’s age influences end-of-life limitations overall and of various LST in ICUs worldwide. DESIGN: Multinational, multicenter, prospective observational study. SETTING: One hundred ninety-nine ICUs in 36 countries worldwide. PATIENTS: Consecutive adult patients admitted to ICUs who died and/or had LST limitations (withholding, withdrawing, or active shortening of the dying process) were included during a 6-month period between September 2015 and September 2016. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Patients were grouped: younger than 65 years, 65–79 years old, and 80 years old or older. A total of 12,200 patients were included. In multivariate logistic regression analysis, odds ratio (OR) for any LST limitation in the 80 years old or older group was higher than in younger than the 65 years old group (OR 1.47 [95% CI, 1.22–1.76], p < 0.001). When stratified by region, this association was significant in Central and Southern Europe (OR 1.56 [95% CI, 1.11–2.20], p = 0.037 and OR 2.23 [95% CI, 1.58–3.17], p < 0.001, respectively), but not in the other regions. The proportion of withholding therapy of each LST was highest in the group of individuals 80 years or older, whereas the proportion of withdrawing therapy was highest in the group younger than 65 years. The 80-year-old or older group also had a shorter time from ICU admission to first limitation. The predominant reason for any LST limitation in all age groups was unresponsiveness to maximal therapy, followed by neurologic and chronic diseases. Patient age was rarely the primary reason for limitations for all groups. CONCLUSIONS: End-of-life limitations were higher in patients 80 years or older compared to those 65 years old or younger, with regional variations. The main reasons for limitations were comparable across age groups, with age not being the primary reason.
- 2 December 2025
- Published by SAGE Publications in Anaesthesia and Intensive Care
- Vol. 54 (1) , 82-83
Changing infusion sets to central lines less frequently: A sustainability quality improvement project
- 2 December 2025
- Published by SAGE Publications in Anaesthesia and Intensive Care
- Vol. 54 (1) , 82-83
Changing infusion sets to central lines less frequently: A sustainability quality improvement project
- 22 October 2025
- Published by SAGE Publications in Anaesthesia and Intensive Care
- Vol. 54 (2) , 140-147
Utility of the NELA score and other variables in predicting the need for ICU admission post emergency laparotomy
The preoperative risk score and key recommendations designed by the National Emergency Laparotomy Audit (NELA) have resulted in improved outcomes for patients undergoing emergency laparotomy. However, the recommended routine intensive care/high dependency unit (ICU) admission for high-risk patients is not always logistically possible and predictive models are needed to identify patients who will benefit. We conducted a study of patients undergoing emergency laparotomy at our tertiary hospital in Western Australia between 2018 and 2023 to identify factors that were associated with the need for ICU admission after emergency laparotomy, as defined by the requirement for a vasopressor infusion, continuous renal replacement therapy or ventilation. Of 1100 patients identified, 875 were included in the primary analysis. In multivariate analysis, the only independent predictive factors of the need for ICU therapies were the American Society of Anesthesiologists grade ( P =0.017) and peak intraoperative serum lactate concentration >2 mmol/L ( P =0.038). An increased NELA score was associated with mortality; however, it was not associated with the requirement for any ICU therapy ( P =0.993). Although only 35.8% of high-risk patients were admitted to ICU, there was no apparent increase in adverse outcomes including mortality or unexpected ICU admission, and 27.4% of patients that were admitted to ICU received no specific therapies. This study provides a basis for the development of new predictive models for ICU admission post emergency laparotomy, and suggests the possibility that routine elective admission might not necessarily add value beyond that achieved by other NELA standards.
- 22 October 2025
- Published by SAGE Publications in Anaesthesia and Intensive Care
- Vol. 54 (2) , 140-147
Utility of the NELA score and other variables in predicting the need for ICU admission post emergency laparotomy
The preoperative risk score and key recommendations designed by the National Emergency Laparotomy Audit (NELA) have resulted in improved outcomes for patients undergoing emergency laparotomy. However, the recommended routine intensive care/high dependency unit (ICU) admission for high-risk patients is not always logistically possible and predictive models are needed to identify patients who will benefit. We conducted a study of patients undergoing emergency laparotomy at our tertiary hospital in Western Australia between 2018 and 2023 to identify factors that were associated with the need for ICU admission after emergency laparotomy, as defined by the requirement for a vasopressor infusion, continuous renal replacement therapy or ventilation. Of 1100 patients identified, 875 were included in the primary analysis. In multivariate analysis, the only independent predictive factors of the need for ICU therapies were the American Society of Anesthesiologists grade ( P =0.017) and peak intraoperative serum lactate concentration >2 mmol/L ( P =0.038). An increased NELA score was associated with mortality; however, it was not associated with the requirement for any ICU therapy ( P =0.993). Although only 35.8% of high-risk patients were admitted to ICU, there was no apparent increase in adverse outcomes including mortality or unexpected ICU admission, and 27.4% of patients that were admitted to ICU received no specific therapies. This study provides a basis for the development of new predictive models for ICU admission post emergency laparotomy, and suggests the possibility that routine elective admission might not necessarily add value beyond that achieved by other NELA standards.
- Open Access
- 14 September 2025
- Published by BMJ in BMJ Health & Care Informatics
- Vol. 32 (1) , e101354
Automated sepsis prediction from unstructured electronic health records using natural language processing: a retrospective cohort study
Objective: Artificial intelligence (AI) holds promise for predicting sepsis. However, challenges remain in integrating AI, natural language processing (NLP) and free text data to enhance sepsis diagnosis at emergency department (ED) triage. This study aimed to evaluate the effectiveness of AI in improving sepsis diagnosis. Methods: This retrospective cohort study analysed data from 134 266 patients admitted to the ED and subsequently hospitalised between 1 January 2016 and 31 December 2021. The data set comprised 10 variables and free-text triage comments, which underwent tokenisation and processing using a bag-of-words model. We evaluated four traditional NLP classifier models, including logistic regression, LightGBM, random forest and neural network. We also evaluated the performance of the BERT classifier. We used area under precision-recall curve (AUPRC) and area under the curve (AUC) as performance metrics. Results: Random forest exhibited superior predictive performance with an AUPRC of 0.789 (95% CI: 0.7668 to 0.8018) and an AUC of 0.80 (95% CI: 0.7842 to 0.8173). Using raw text, the BERT model achieved an AUPRC of 0.7542 (95% CI: 0.7418 to 0.7741) and AUC of 0.7735 (95% CI: 0.7628 to 0.8017) for sepsis prediction. Key variables included ED treatment time, patient age, arrival-to-treatment time, Australasian Triage Scale and visit type. Discussion: This study demonstrates AI, particularly random forest and BERT classifiers, for early sepsis detection in EDs using free-text patient concerns. Conclusion: Incorporating free text into machine learning improved diagnosis and identified missed cases, enhancing sepsis prediction in the ED with an AI-powered clinical decision support system. Large, prospective studies are needed to validate these findings.
- 14 September 2025
- Published by BMJ in BMJ Health & Care Informatics
- Vol. 32 (1) , e101354
Open AccessAutomated sepsis prediction from unstructured electronic health records using natural language processing: a retrospective cohort study
Objective: Artificial intelligence (AI) holds promise for predicting sepsis. However, challenges remain in integrating AI, natural language processing (NLP) and free text data to enhance sepsis diagnosis at emergency department (ED) triage. This study aimed to evaluate the effectiveness of AI in improving sepsis diagnosis. Methods: This retrospective cohort study analysed data from 134 266 patients admitted to the ED and subsequently hospitalised between 1 January 2016 and 31 December 2021. The data set comprised 10 variables and free-text triage comments, which underwent tokenisation and processing using a bag-of-words model. We evaluated four traditional NLP classifier models, including logistic regression, LightGBM, random forest and neural network. We also evaluated the performance of the BERT classifier. We used area under precision-recall curve (AUPRC) and area under the curve (AUC) as performance metrics. Results: Random forest exhibited superior predictive performance with an AUPRC of 0.789 (95% CI: 0.7668 to 0.8018) and an AUC of 0.80 (95% CI: 0.7842 to 0.8173). Using raw text, the BERT model achieved an AUPRC of 0.7542 (95% CI: 0.7418 to 0.7741) and AUC of 0.7735 (95% CI: 0.7628 to 0.8017) for sepsis prediction. Key variables included ED treatment time, patient age, arrival-to-treatment time, Australasian Triage Scale and visit type. Discussion: This study demonstrates AI, particularly random forest and BERT classifiers, for early sepsis detection in EDs using free-text patient concerns. Conclusion: Incorporating free text into machine learning improved diagnosis and identified missed cases, enhancing sepsis prediction in the ED with an AI-powered clinical decision support system. Large, prospective studies are needed to validate these findings.
- Open Access
- 2 March 2025
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 69 (4) , e70009
Preferences for thromboprophylaxis in the intensive care unit: An international survey
Background: Venous thromboembolism (VTE) is a frequent complication in critically ill patients, who often have multiple risk factors. Pharmacological thromboprophylaxis is widely applied to lower this risk, but guidelines lack dosing recommendations.Objective: This survey aims to assess current thromboprophylaxis preferences and willingness to participate in future randomized clinical trials (RCTs) on this topic.Method: We conducted an international online survey between February and May 2023 among intensive care unit (ICU) physicians, including 16 questions about preferences in relation to thromboprophylaxis and preferences on topics for a future RCT. The survey was distributed through the network of the Collaboration for Research in Intensive Care.Results: A total of 715 physicians from 170 ICUs in 23 countries contributed information, with a mean response rate of 36%. In most ICUs, both pharmacological (n = 166, 98%) and mechanical thromboprophylaxis (n = 143, 84%) were applied. A total of 36 pharmacological thromboprophylaxis regimens were reported. Use of low‐molecular‐weight heparin (LMWH) was most common (n = 149 ICUs, 87%), followed by subcutaneous unfractionated heparin (n = 44 ICUs, 26%). Seventy‐five percent of physicians indicated that they used enoxaparin 40 mg (4000 IU), dalteparin 5000 IU, or tinzaparin 4500 IU once daily, whereas 25% reported the use of 16 other LMWH type and dose combinations. Dose adjustment according to weight was common (78 ICUs, 46%). Participants perceived high variation in the application of thromboprophylaxis and were willing to consider an alternative LMWH type (n = 542, 76%) or dose (n = 538, 75%) in the context of an RCT.Conclusion: LMWH was the preferred agent for thromboprophylaxis in critically ill patients. There was considerable variation in the application of LMWH for prophylaxis, reflected by the use of different types, doses, and dosing strategies. Most physicians would be willing to participate in an RCT on thromboprophylaxis.Editorial comment: This survey demonstrates current patterns in implementation preferences for critically ill patients. While there is one approach and drug that is commonly preferred, these findings show that there is some variation in practice.
- 2 March 2025
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 69 (4) , e70009
Open AccessPreferences for thromboprophylaxis in the intensive care unit: An international survey
Background: Venous thromboembolism (VTE) is a frequent complication in critically ill patients, who often have multiple risk factors. Pharmacological thromboprophylaxis is widely applied to lower this risk, but guidelines lack dosing recommendations.Objective: This survey aims to assess current thromboprophylaxis preferences and willingness to participate in future randomized clinical trials (RCTs) on this topic.Method: We conducted an international online survey between February and May 2023 among intensive care unit (ICU) physicians, including 16 questions about preferences in relation to thromboprophylaxis and preferences on topics for a future RCT. The survey was distributed through the network of the Collaboration for Research in Intensive Care.Results: A total of 715 physicians from 170 ICUs in 23 countries contributed information, with a mean response rate of 36%. In most ICUs, both pharmacological (n = 166, 98%) and mechanical thromboprophylaxis (n = 143, 84%) were applied. A total of 36 pharmacological thromboprophylaxis regimens were reported. Use of low‐molecular‐weight heparin (LMWH) was most common (n = 149 ICUs, 87%), followed by subcutaneous unfractionated heparin (n = 44 ICUs, 26%). Seventy‐five percent of physicians indicated that they used enoxaparin 40 mg (4000 IU), dalteparin 5000 IU, or tinzaparin 4500 IU once daily, whereas 25% reported the use of 16 other LMWH type and dose combinations. Dose adjustment according to weight was common (78 ICUs, 46%). Participants perceived high variation in the application of thromboprophylaxis and were willing to consider an alternative LMWH type (n = 542, 76%) or dose (n = 538, 75%) in the context of an RCT.Conclusion: LMWH was the preferred agent for thromboprophylaxis in critically ill patients. There was considerable variation in the application of LMWH for prophylaxis, reflected by the use of different types, doses, and dosing strategies. Most physicians would be willing to participate in an RCT on thromboprophylaxis.Editorial comment: This survey demonstrates current patterns in implementation preferences for critically ill patients. While there is one approach and drug that is commonly preferred, these findings show that there is some variation in practice.
- Open Access
- 20 February 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (2) , e0315170
Muscle growth and anabolism in intensive care survivors (GAINS 2.0): Protocol for a multi-centre randomised; placebo controlled clinical trial of nandrolone in deconditioned adults recovering from critical illness
Background: Intensive care patients can experience significant long-term impairment in mobility and function caused by their critical illness. A potential contributory factor apart from critical illness polymyoneuropathy is the low levels of anabolic hormones in these patients. Testosterone levels in critically ill patients are extremely low, even in the latter recovery phase. A potential solution to critical illness myopathy may be to provide anabolic support in addition to standard care (early physiotherapy) to further improve gains in strength. Research question: This project aims to test whether a synthetic testosterone (nandrolone) improves muscle strength in ICU survivors compared to placebo. Methods: GAINS 2.0 is a multicentre, randomised, double blinded placebo-controlled trial which will allocate ICU patients in a 1:1 ratio to nandrolone compared to placebo which commenced recruitment in July 2023. Adult patients admitted to the ICU, receiving nutrition for a minimum of 24 hours with an ICU stay of at least 5 days, or patients with significant weakness as result of their ICU stay (such that they are unable to mobilise independently) will be eligible to participate. Sample size will be 54 patients. Patients will be randomised to receive nandrolone 100mg (males) / 50mg(females) weekly for 3 weeks in addition to standard care. The co-primary outcomes are the time to walking with one person assisting (Intensive Care Mobility scale = 8 or more, in days from randomisation), change in muscle strength measured by the Medical Research Council (MRC) muscle strength sum score from enrolment to hospital discharge and number of days out of hospital up to day 90 post-discharge. Secondary outcomes are grip strength measured by hand-held dynamometry. SF-36 scores (quality of life and functional domains), and days to return to work, for those working pre-ICU, will be collected via a 3-month phone follow-up. Conclusions: A previous pilot feasibility trial showed that nandrolone is safe and feasible. We hypothesize nandrolone will improve muscle strength and physical functioning at hospital discharge and at follow-up. The results of this trial may have significant interest to clinicians and patients considering the large and increasing number of patients surviving intensive care but with physical impairment. This trial may have significant implications on lowering hospital costs and daily adjusted life years. Trial registry: anzctr.org.au; No.: ACTRN12623000729628 URL: anzctr.org.au.
- 20 February 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (2) , e0315170
Open AccessMuscle growth and anabolism in intensive care survivors (GAINS 2.0): Protocol for a multi-centre randomised; placebo controlled clinical trial of nandrolone in deconditioned adults recovering from critical illness
Background: Intensive care patients can experience significant long-term impairment in mobility and function caused by their critical illness. A potential contributory factor apart from critical illness polymyoneuropathy is the low levels of anabolic hormones in these patients. Testosterone levels in critically ill patients are extremely low, even in the latter recovery phase. A potential solution to critical illness myopathy may be to provide anabolic support in addition to standard care (early physiotherapy) to further improve gains in strength. Research question: This project aims to test whether a synthetic testosterone (nandrolone) improves muscle strength in ICU survivors compared to placebo. Methods: GAINS 2.0 is a multicentre, randomised, double blinded placebo-controlled trial which will allocate ICU patients in a 1:1 ratio to nandrolone compared to placebo which commenced recruitment in July 2023. Adult patients admitted to the ICU, receiving nutrition for a minimum of 24 hours with an ICU stay of at least 5 days, or patients with significant weakness as result of their ICU stay (such that they are unable to mobilise independently) will be eligible to participate. Sample size will be 54 patients. Patients will be randomised to receive nandrolone 100mg (males) / 50mg(females) weekly for 3 weeks in addition to standard care. The co-primary outcomes are the time to walking with one person assisting (Intensive Care Mobility scale = 8 or more, in days from randomisation), change in muscle strength measured by the Medical Research Council (MRC) muscle strength sum score from enrolment to hospital discharge and number of days out of hospital up to day 90 post-discharge. Secondary outcomes are grip strength measured by hand-held dynamometry. SF-36 scores (quality of life and functional domains), and days to return to work, for those working pre-ICU, will be collected via a 3-month phone follow-up. Conclusions: A previous pilot feasibility trial showed that nandrolone is safe and feasible. We hypothesize nandrolone will improve muscle strength and physical functioning at hospital discharge and at follow-up. The results of this trial may have significant interest to clinicians and patients considering the large and increasing number of patients surviving intensive care but with physical impairment. This trial may have significant implications on lowering hospital costs and daily adjusted life years. Trial registry: anzctr.org.au; No.: ACTRN12623000729628 URL: anzctr.org.au.
- Open Access
An implementation-effectiveness trial investigating feasibility, safety and efficacy of Best pRacticE guideline cAre physioTHErapy with addition of protocolised ventilator hyperinflation on patient-important outcomes for critically ill adults intUbated and ventilated with Pneumonia. (BREATHE UP)
Pneumonia is a common cause for intensive care unit (ICU) admission for breathing support from a mechanical ventilator, resulting in high morbidity, mortality, and healthcare costs. Physiotherapists working in ICU treat patients with critical pneumonia using a range of respiratory treatments to improve breathing, hasten weaning from the ventilator, and restore functional independence. Evidence supports the short-term benefits of these treatments, however currently no standard of physiotherapy practice exists for these ICU patients. Despite a plethora of studies which have shown that physiotherapy treatments, such as ventilator lung hyperinflation (VHI), aid the lungs to work better short-term, there are no studies to date which investigate the effect of these important treatments on meaningful patient-important outcomes, such as earlier weaning from the ventilator, earlier hospital discharge, less breathlessness and lung secretions, short- and longer-term disability, health- related quality of life and survival. Through previous multiphase mixed-methods research, a clinical practice guideline was developed outlining best physiotherapy practice for this ICU patient cohort. This proposed research involves conducting a multicentre hybrid implementation-effectiveness randomised, controlled trial which aims to: evaluate implementation of physiotherapy guideline care for management of pneumonia in ICU regarding feasibility, safety and acceptability; and to determine the safety and effectiveness of a standardised dosage of daily ventilator hyperinflation in addition to standard guideline care on patient-important outcomes, health system outcomes; and cost effectiveness. This study will address critical knowledge gaps in the ICU physiotherapy evidence base regarding the impact of a course of standardised, best practice respiratory physiotherapy intervention during the ICU stay for patients with critical pneumonia requiring invasive mechanical ventilation, provide valuable information for clinicians to inform clinical practice regarding treatable traits and streamlining care to promote clinical efficiency, and determine the impact of respiratory physiotherapy care on patient-important and health service outcomes. Trial registration: ANZ Clinical trials Registry number ACTRN12624001130550.
Open AccessAn implementation-effectiveness trial investigating feasibility, safety and efficacy of Best pRacticE guideline cAre physioTHErapy with addition of protocolised ventilator hyperinflation on patient-important outcomes for critically ill adults intUbated and ventilated with Pneumonia. (BREATHE UP)
Pneumonia is a common cause for intensive care unit (ICU) admission for breathing support from a mechanical ventilator, resulting in high morbidity, mortality, and healthcare costs. Physiotherapists working in ICU treat patients with critical pneumonia using a range of respiratory treatments to improve breathing, hasten weaning from the ventilator, and restore functional independence. Evidence supports the short-term benefits of these treatments, however currently no standard of physiotherapy practice exists for these ICU patients. Despite a plethora of studies which have shown that physiotherapy treatments, such as ventilator lung hyperinflation (VHI), aid the lungs to work better short-term, there are no studies to date which investigate the effect of these important treatments on meaningful patient-important outcomes, such as earlier weaning from the ventilator, earlier hospital discharge, less breathlessness and lung secretions, short- and longer-term disability, health- related quality of life and survival. Through previous multiphase mixed-methods research, a clinical practice guideline was developed outlining best physiotherapy practice for this ICU patient cohort. This proposed research involves conducting a multicentre hybrid implementation-effectiveness randomised, controlled trial which aims to: evaluate implementation of physiotherapy guideline care for management of pneumonia in ICU regarding feasibility, safety and acceptability; and to determine the safety and effectiveness of a standardised dosage of daily ventilator hyperinflation in addition to standard guideline care on patient-important outcomes, health system outcomes; and cost effectiveness. This study will address critical knowledge gaps in the ICU physiotherapy evidence base regarding the impact of a course of standardised, best practice respiratory physiotherapy intervention during the ICU stay for patients with critical pneumonia requiring invasive mechanical ventilation, provide valuable information for clinicians to inform clinical practice regarding treatable traits and streamlining care to promote clinical efficiency, and determine the impact of respiratory physiotherapy care on patient-important and health service outcomes. Trial registration: ANZ Clinical trials Registry number ACTRN12624001130550.